{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Large+Cell+Lymphoma+Relapsed%2FRefractory&page=4", "query": { "condition": "Diffuse Large Cell Lymphoma Relapsed/Refractory", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 592, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Large+Cell+Lymphoma+Relapsed%2FRefractory&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Large+Cell+Lymphoma+Relapsed%2FRefractory&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T14:51:10.431Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01719250", "title": "Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Transformed Recurrent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Buparlisib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2012-12", "completion_date": "2017-03-22", "has_results": false, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01719250" }, { "nct_id": "NCT05544968", "title": "Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Disease", "CD30-Positive Diffuse Large B-Cell Lymphoma", "CD30+ Anaplastic Large Cell Lymphoma", "CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma", "CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma", "Leukemia", "Lymphoma" ], "interventions": [ { "name": "anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-03-04", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544968" }, { "nct_id": "NCT04007029", "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD19 Positive", "CD20 Positive", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2019-10-04", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04007029" }, { "nct_id": "NCT00504751", "title": "Phase II Study of \"VIPER\" Chemotherapy in Rel/Ref DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "bortezomib, dexamethasone, ifosfamide", "type": "DRUG" }, { "name": "mesna, cisplatin, etoposide, rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2007-05", "completion_date": "2012-02-17", "has_results": true, "last_update_posted_date": "2017-04-07", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00504751" }, { "nct_id": "NCT02252146", "title": "Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "IMO-8400", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idera Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2014-06", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 12, "location_summary": "Los Angeles, California • Atlanta, Georgia • Decatur, Illinois + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02252146" }, { "nct_id": "NCT00086944", "title": "Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma" ], "interventions": [ { "name": "oblimersen sodium", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2004-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086944" }, { "nct_id": "NCT05645744", "title": "Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "Chronic Lymphocytic Leukemia in Relapse", "Small Lymphocytic Lymphoma, Relapsed", "Waldenstrom's Macroglobulinemia Recurrent", "Follicular B-cell Non-Hodgkin's Lymphoma", "B-cell Lymphoma Refractory", "Mantle Cell Lymphoma Recurrent", "Hairy Cell Leukemia", "Diffuse Large B Cell Lymphoma", "Waldenstrom's Macroglobulinemia Refractory", "Mantle Cell Lymphoma Refractory" ], "interventions": [ { "name": "Prior MB-102 CAR-T cell investigational product.", "type": "BIOLOGICAL" }, { "name": "Prior MB-106 CAR-T cell investigational product.", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mustang Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-09-29", "completion_date": "2024-04-12", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 5, "location_summary": "Orange, California • Boston, Massachusetts • Rochester, New York + 2 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645744" }, { "nct_id": "NCT04231747", "title": "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma Non-Hodgkin", "Agressive Lymphoma", "Diffuse-large B-cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "CC-97540", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-05-21", "completion_date": "2024-02-01", "has_results": false, "last_update_posted_date": "2024-05-20", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04231747" }, { "nct_id": "NCT00453206", "title": "Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 66, "start_date": "2007-02", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00453206" }, { "nct_id": "NCT01998035", "title": "Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoid Malignancies", "Lymphoma", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "RomiDEPsin 10 MG/M2", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 100 MG", "type": "DRUG" }, { "name": "Romidepsin 14 MG/M2", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 200 MG", "type": "DRUG" }, { "name": "Oral 5-Azacitidine 300 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2013-11", "completion_date": "2020-01-06", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-11-09T14:51:10.431Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998035" } ] }